A Study of Daratumumab
Public ClinicalTrials.gov record NCT05438043. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
Study identification
- NCT ID
- NCT05438043
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 500 participants
Conditions and interventions
Conditions
Interventions
- Carfilzomib Drug
- Daratumumab Drug
- Dexamethasone Drug
- Lenalidomide Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2022
- Primary completion
- Jan 30, 2029
- Completion
- Jan 30, 2029
- Last update posted
- May 7, 2026
2022 – 2029
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami Sylvester Cancer Center | Miami | Florida | 33136 | Active, not recruiting |
| Emory University | Atlanta | Georgia | 30322 | Active, not recruiting |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | Active, not recruiting |
| Barnes-jewish Hospital | St Louis | Missouri | 63108 | Active, not recruiting |
| Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg | New York | New York | 10029 | Completed |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Completed |
| Baylor University Medical Center | Dallas | Texas | 75246 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05438043, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05438043 live on ClinicalTrials.gov.